A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

Trial Profile

A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Taliglucerase alfa (Primary)
  • Indications Gaucher's disease
  • Focus Therapeutic Use
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 27 Jun 2014 According to a Protalix media release, 36-month safety and efficacy results were presented at the 11th meeting of the European Working Group on Gaucher Disease.
    • 19 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top